| Jemal,et al. in based on the global cancer statistics: Lung cancer was themost commonly diagnosed cancer as well as the leading cause of cancer deathin males in2008globally. Among females, it was the fourth most commonlydiagnosed cancer and the second leading cause of cancer death. Lung cancerhas become a serious harm to people’s health and life, tumor formation,development and metastasis is a complex physiology process, in which newangiogenesis plays a vital role. In recent years,with the deepening of the themolecular biology,s research,angiogenesis and anti-angiogenesis factorsbecome the focus of research. Vascular endothelial growth factor (VEGF) isthe strongest and most specific angiogenesis regulation factor. Endostatin(ES)is still one of the most effective endogenous vascular growth inhibitor, was byFolkman lab O ’reilly, et al in rat vascular endothelial cell tumor cell culturefluid extraction of a protein in1997. In the body of the endogenousangiogenesis inhibitors, endostatin has extensive antitumor activity. Theendogenous angiogenesis inhibitors of the body, endostatin has extensiveanti-tumor activity. Many clinical studies have shown that a variety ofmalignant tumors in patients with pleural effusion ES and VEGF levewiththe tumor changing appeared to reduce or increase. Joint detection of lungcancer patients serum levels of VEGF and the expression of pleural effusion,s endostatin, it is reported uncommonly thatrelation between tumor staging,metastasis and them, this research is mainly through the method of double antibody sandwich enzyme-linked immunosorbent (ELISA) detection ofhealthy subjects and lung cancer patients serum and pleural effusionVEGF-A, VEGF-C, VEGFR-3and the expression level of ES, through thecomparison, analysis between healthy people and patients with lung cancerand patients at different stages of lung cancer between the factor ofexpression changes; Understanding and analyzing of the differences,exploringand revealing the relevant laws, for lung cancer patients with auxiliarydiagnosis, classification and staging evaluation providing the theoryreference and different approachs for tumor treatment.Methods：Selecting without any antitumor treatment of32cases ofprimary lung cancer patients for the experimental group,10healthy subjectsas control group. Respectively as required to extract serum specimens of lungcancer patients and healthy people, and to extract merger pleural effusion oflung cancer patients with pleural effusion. The expression level of VEGF-A，VEGF-C，VEGFR-3and ES in serum specimens of lung cancer patients andhealthy people, and in pleural effusion of lung cancer patients were detectedthrouth ELISA assay. Making statistical analysis comparison, SPSS13.0software was used to analyze all data, Difference between measurement datawas setted with group t test, compared with related t test, correlation analysisusing the linear regression,the difference is statistically significant with P <0.05.Results：1Lung cancer patients and healthy controls serum ES expressionlevel were respective（402.72±27.97）ng/mL、（379.42±37.22）ng/mL；Lungcancer patients and healthy controls serum VEGF-A level were respective（403.20±21.63）ng/L、（381.08±27.00）ng/L；Lung cancer patients and healthy controls, the serum level of VEGF-C were respective（490.65±66.00）ng/L、（468.21±25.55）ng/L；Lung cancer patients and healthy controls serumVEGFR-3level were respectiv（e1163.52±97.25）ng/L、（934.83±77.03）ng/L。The indexes, compared to patients with lung cancer serum ES, VEGF-A andVEGFR-3, were higher than the healthy people, there is statisticalsignificance (P <0.05).Lung cancer patients serum level of VEGF-Ccompared with healthy people, it is not statistical significance (P>0.05).2Lung adenocarcinoma ES expression level in serum and lungsquamous carcinoma patients, were respective （396.78±27.78） ng/mL、（412.64±26.46）ng/mL；Lung adenocarcinoma and VEGF-A in serum oflung squamous carcinoma level were respective （409.77±23.15）ng/L、（392.23±13.56）ng/L; Adenocarcinoma of the lung and lung squamouscarcinoma patients serum level of VEGF-C, were respective（493.06±68.34）ng/L、（486.63±64.64）ng/L；Lung adenocarcinoma VEGFR-3level in serumand lung squamous carcinoma patients, were respective（1163.10±110.92）ng/L、（1164.21±73.49）ng/L.The indexes, compared with lung squamouscarcinoma patients, serum VEGF-A of the adenocarcinoma was higher,it isstatistically significant (P <0.05). Lung adenocarcinoma in serum ES,VEGF-C and VEGFR-3were compared with squamous carcinoma patients,it is not statistically significant (p>0.05).3Lung cancer patients in stage I and stage IV,ES expression level inserum, was respective（398.66±12.75）ng/mL、（404.57±32.77）ng/mL；Lungcancer patients in stage I and stage IV,serum VEGF-A level was respective（402.80±16.22）ng/L、（403.38±24.04）ng/L；Lung cancer patients in stageI and stage IV,serum level of VEGF-C,was respective（461.14±20.14）ng/L、 （504.06±75.19）ng/L； Lung cancer patients in stage I and stage IV,VEGFR3serum levels, was respective （1026.32±74.72） ng/L、（1165.56±111.40）ng/L。The indexe, compared serum VEGF-C andVEGFR3of the lung cancer patients in stage I with IV, wasstatistically significant (P <0.05). The indexe, compared serum ES、VEGF-A of the lung cancer patients with IV，it is not statistical significance(P>0.05).4ES expression in Cancerous pleufral effusion and lung cancer patientsserum levels was respective（416.83±45.90）ng/mL、（402.72±27.97）ng/Ml；VEGF-A expression in Cancerous pleural effusion and lung cancer patientsserum levels was respective（410.43±47.12）ng/L、（403.20±21.63）ng/L；VEGF-C expression in Cancerous pleural effusion and lung cancer patientsserum levels was respective（505.21±57.89） ng/L、（490.65±66.00）ng/L；VEGFR3expression in Cancerous pleural effusion and lung cancer patientsserum levels was respective （1225.14±70.29）ng/L、（1163.52±97.25）ng/L.Compared to the data，VEGFR-3in Cancerous pleural effusion is higherthan the expression level in the serum lung cancer,it was statisticallysignificant (P <0.05). ES、VEGF-A、VEGF-C in Cancerous pleural effusionLevel was compared with lung cancer in serum without statistical significance.(P>0.05).5ES expression level in Cancerous pleural effusion of Lungadeno-carcinoma cancerous and lung squamous cell carcinoma was respective（418.82±39.29）ng/mL、（413.24±61.10）ng/mL；VEGF-Aexpression levelin Cancerous pleural effusion of Lung adenocarcinoma cancerous and lungsquamous cell carcinoma was respective （422.84±34.82） ng/L、 （388.09±61.80）ng/L；VEGF-C expression level in Cancerous pleuraleffusion of Lung adenocarcinoma cancerous and lung squamous cellcarcinoma was respective（501.69±56.04）ng/L、（511.54±67.31）ng/L；VEGFR-3expression level in Cancerous pleural effusion of Lungadeno-carcinoma cancerous and lung squamous cell carcinoma was respective（1243.05±45.67）ng/L、（1192.92±99.34）ng/L。VEGFR-3expression levelin Cancerous pleural effusion of Lung adenocarcinoma cancerous is higherthan lung squamous cell carcinoma，it was statistically significant (P <0.05).The expression level in Cancerous pleural effusion of Lungadenocarcinoma cancerous was compared with lung squamous, it wasstatistical significance.(P>0.05).614patients with of lung cancer merger cancerous pleural effusion， ESin pleural effusion and serum、VEGF-A in pleural effusion and theserum、VEGF-C in pleural effusion and the serum、VEGFR3in pleural effusion andthe serum level.according to respectivelty two comparison employ PearsonCorrelation, there were no correlations between four factors.7. In32patients lung cancer serum, ES,VEGF-A, the VEGF-C andVEGFR-3levels were compared by linear correlation between two: ES andVEGFR-3in the serum were positively correlated(r=0.438， P=0.012);VEGF-C and VEGFR3in the serum were positively correlated(r=0.446， P=0.011)。Conclusions：1. The serum ES, VEGF-A and VEGFR3in lung cancer patients arehigher than the healthy people, there is statistical significance (P <0.05).2. VEGF–A of lung adenocarcinoma serum is higher than squamous carcinoma serum, it was statistically significant (P <0.05).Serum VEGF-Cand VEGFR3of the lung cancer Patients in stage Iwere compared with that instage IV, it was statistically significant (p <0.05). VEGFR3in theCancerous pleural effusion is higher than lung cancer the expression levelin the serum, it was statistically significant (p <0.05). |
PDF Full Text Request